SMC has recommended that Zinbryta can be prescribed if you have:
- rapidly evolving severe (RES) relapsing remitting MS or
- relapsing remitting MS an inadequate response to disease modifying therapy.
This follows last month's decision from NICE to approve Zinbryta as a treatment for relapsing remitting MS for the NHS in England and Wales.
This is excellent news. The approval of Zinbryta in Scotland expands the range of disease modifying drugs by offering a different dosing schedule, a different mode of action and a different profile of benefits and risks compared to existing disease modifying drugs. Choosing a disease modifying is an important decision which should be made in consultation with your neurologist and MS specialist nurse.
Pam Macfarlane, Chief Executive Officer, MS Trust
Zinbryta (daclizumab) is a disease modifying drug which is self-injected at home once a month. The drug was licensed by the European Medicines Agency in July 2016.
In clinical trials, Zinbryta reduced the number of relapses by about 50% compared to placebo and reduced the number of relapses by 45% compared to beta interferon.
The most common side effects of Zinbryta include infections or swelling of the chest,nose and throat, increased levels of liver enzymes, skin rash or eczema, depression and swollen lymph glands.
Less common, but more severe side effects include serious infections, serious skin reactions and liver damage.